Sudarshan Pharma Industries is currently trading at Rs. 82.80, up by 1.25 points or 1.53% from its previous closing of Rs. 81.55 on the BSE.
The scrip opened at Rs. 82.50 and has touched a high and low of Rs. 82.80 and Rs. 82.50 respectively. So far 8000 shares were traded on the counter.
The BSE group 'M' stock of face value Rs. 10 has touched a 52 week high of Rs. 91.90 on 23-Aug-2023 and a 52 week low of Rs. 51.85 on 31-Mar-2023.
Last one week high and low of the scrip stood at Rs. 91.90 and Rs. 73.00 respectively. The current market cap of the company is Rs. 199.27 crore.
The promoters holding in the company stood at 57.39%, while Institutions and Non-Institutions held 3.58% and 39.03% respectively.
Sudarshan Pharma Industries has incorporated subsidiary company in the name and style of Lifescience Chemicals Private Limited (name is approved by the MCA) in the state of Gujarat. The company has incorporated subsidiary company on August 23, 2023. The company has a similar line of business with expertise in chemical and chemical compounds including speciality chemicals, ingredients, by? products and their related preparations articles and products, further this acquisition is for expansion and enhancements of verticals of business
Earlier, the company had received approval to incorporate a subsidiary company in the name and style of Lifescience Chemical (name is approved by the MCA) in the state of Gujarat representing 51% of the shareholding of Lifescience Chemical making it a Subsidiary Company.
Sudarshan Pharma Industries is engaged in contract manufacturing, outsource & Supply of Generic Pharma formulation and medicines to healthcare institution, Government, NGO and Hospitals.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: